SCHEMBL3308684

SCHEMBL3308684

Cc1sc(C(N)=O)nc1-c1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
PKM P14618 2/20 0.55
SCN9A Q15858 1/20 0.52
HTT P42858 1/20 0.46
PTGS2 P35354 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
ROCK2 O75116 1/20 0.41
RARA P10276 1/20 0.41
RARB P10826 1/20 0.41
RARG P13631 1/20 0.41
IKBKB O14920 3/20 0.41
CHUK O15111 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
JAK2 O60674 1/20 0.41
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
GRM2 Q14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3310365 0.87 SCN9A (0.51) ALDH1A1PKMSCN9ANPSR1ROCK2
SCHEMBL3308450 0.84 SCN9A (0.57) ALDH1A1PKMSCN9ANPSR1ROCK2
SCHEMBL3311820 0.82 ALDH1A1 (0.59) ALDH1A1PKMSCN9AHTTPTGS2
SCHEMBL3178699 0.79 GAA (0.48) ALDH1A1PKMHTTPTGS2NPSR1
SCHEMBL3185077 0.77 PTGDR2 (0.43) SCN9A
SCHEMBL4761846 0.76 PTGS2 (0.54) ALDH1A1PKMPTGS2NPSR1IKBKB
SCHEMBL7459503 0.76 PTGDR2 (0.43)
SCHEMBL131267 0.75 SMN1; SMN2 (0.65) ALDH1A1PKMHTTNPSR1KDM4E
SCHEMBL8188473 0.74 ALDH1A1 (0.61) ALDH1A1PKMHTTPTGS2NPSR1
SCHEMBL3313394 0.74 SCN9A (0.57) SCN9AIKBKBJAK2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2384320-B1 PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2015-03-04 EP disclosed
US-8629157-B2 Pyrrolidine compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-14 US disclosed
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 EP disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-20120142677-A1 Pyrrolidine Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 ALDH1A1 802/4885PKM 3680/4885SCN9A 2008/4885
US-20120142677-A1 Pyrrolidine Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 ALDH1A1 3279/4885PKM 2979/4885SCN9A 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.